Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Glioblastoma Multiforme Market Revenue Growth Supported By A CAGR Of 3.93% Through 2030

The market for glioblastoma multiforme treatments experienced a significant expansion recently, and this upward trajectory is projected to continue. It is anticipated to grow from $2.7 billion in 2025 to $2.92 billion in 2026, reflecting a compound annual growth rate of 8.1%. Factors contributing to this expansion in the past include a scarcity of therapeutic choices, progress in the field of neuro-oncology, the establishment of standardized chemotherapy protocols, an increase in cancer research facilities, and enhancements in medical imaging capabilities.

The glioblastoma multiforme sector is poised for considerable expansion in the upcoming years, projected to reach a valuation of $3.94 billion by 2030, driven by a compound annual growth rate of 7.8%. This anticipated growth stems from advancements in the creation of innovative targeted pharmaceuticals, intensified immunotherapy research initiatives, the increasing embrace of individualized cancer therapies, augmented financial investment in brain cancer studies, and a heightened emphasis on enhancing patient survival rates. Key developments shaping the forecast period involve a greater concentration on specific cancer treatments, a surge in the utilization of diverse therapeutic strategies, the broadening scope of precision oncology investigations, a growing deployment of sophisticated diagnostic imaging techniques, and an overall improvement in engagement with clinical trials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

Glioblastoma Multiforme Market Growth Factors Supporting Long-Term Expansion

The escalating prevalence of brain disorders is poised to be a primary catalyst for the glioblastoma multiforme market’s expansion. Conditions affecting brain structure or function, resulting in impairments in cognitive, emotional, or physical capabilities, are increasingly observed. Factors contributing to this surge include an aging demographic, extended lifespans, evolving lifestyle patterns, and enhanced diagnostic technologies. Investigating these neurological conditions facilitates progress in glioblastoma multiforme (GBM) research, paving the way for earlier detection, novel therapeutic interventions, and enhanced patient prognoses. Such research efforts can illuminate the genetic and molecular pathways implicated in GBM’s onset. As an illustration, Dementia Australia reported in February 2025 that roughly 433,300 individuals in Australia are currently affected by dementia, a figure predicted to ascend to 812,500 by 2054. Furthermore, dementia commencing at a younger age impacts approximately 29,000 individuals in 2025, with estimates suggesting this number will climb to 41,000 by 2054. Consequently, the growing incidence of brain disorders is a significant driver for the glioblastoma multiforme market.

Glioblastoma Multiforme Market Segment Analysis Highlighting Growth Areas

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Glioblastoma Multiforme Market Industry Trends Shaping Future Revenue Growth

In the glioblastoma multiforme sector, leading entities are directing their efforts towards pioneering innovative treatments, specifically CAR T-cell therapies, in an endeavor to meet the significant unmet medical requirements presented by this aggressive form of cancer. This immunotherapy approach entails the genetic alteration of a patient’s own T-cells, equipping them with the capability to more precisely identify and eradicate malignant cells. Illustrating this trend, Chimeric Therapeutics Limited, a biotechnology firm situated in Australia, initiated a Phase IB clinical investigation in June 2023 for its CHM 1101 (CLXT CAR T) treatment, targeting patients experiencing recurrent or advancing glioblastoma multiforme (GBM). This multi-center study is designed to thoroughly assess the treatment’s safety profile and effectiveness, concurrently establishing the optimal dosage for subsequent Phase 2 studies. Positive preliminary findings from the Phase 1a stage indicated disease stabilization, and this new trial seeks to leverage those early successes to propel the therapy towards broader clinical application. The company intends to utilize the gathered evidence to formulate the design for a pivotal registration trial and solicit guidance from regulatory bodies.

Glioblastoma Multiforme Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Access The Complete Glioblastoma Multiforme Market Report:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Glioblastoma Multiforme Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the glioblastoma multiforme market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model